Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model.

Author: Sanbao CHAI ¹ ; Shuqing YU ² ; Fengqi LIU ² ; Zuoxiang LIU ² ; Qingqing YANG ² ; Feng SUN ²
Author Information

1. Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing 102206, China.
2. Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing 100191, China.
Publication Type:Journal Article
MeSH: Humans; Incretins/therapeutic use*; Diabetes Mellitus, Type 2/drug therapy*; Hypoglycemic Agents/therapeutic use*; Risk Assessment
From: Chinese Medical Journal 2023;136(1):102-104
CountryChina
Language:English